Market Overview

Bonti Appoints Dr. Jacob Chacko to Board of Directors


Bonti, a privately-held, clinical-stage biotechnology company, today
announced the appointment of Dr. Jacob Chacko to its Board of Directors,
effective immediately. Dr. Chacko has served as the Chief Financial
Officer of Ignyta, Inc. (NASDAQ:RXDX) since May 2014. At Ignyta, he
leads multiple functions, including Finance, Accounting, Investor
Relations, Communications, Facility Operations, and IT, and has helped
lead over $500 million in capital raises. He was part of the management
team that helped guide the company through the successful acquisition by
Roche in December 2017. He is succeeding director David Ramsay, who has
been a long-standing director of Bonti since 2015 and is making a
planned transition from the Board to the company management as Chief
Financial Officer, as announced previously.

"It is a pleasure to welcome Jacob as a member of our Board of
Directors," said Jonathan Lim, M.D., Chairman and co-founder of Bonti.
"His deep experience building, growing and financing organizations will
be invaluable as we continue to rapidly advance our clinical-stage
pipeline and prepare for the next stage of Bonti's development, on the
back of topline data from our pain (LANTERN-1) program in the coming
months." He added, "We would also like to thank David Ramsay for his
years of service on Bonti's Board, helping guide us during our initial
years of growth to a Phase 2 stage company, with multiple programs
ongoing simultaneously."

"I am delighted to join Bonti's board at this exciting inflection point
for the company," said Dr. Chacko. "The experience of the Bonti
management team in the neurotoxin field along with a steadily advancing
clinical pipeline positions the company well for future success. I look
forward to working closely with the board and management team in
advancing Bonti's novel treatment paradigms to address unmet therapeutic
and medical aesthetic needs of millions of patients."

Prior to Ignyta, Dr. Chacko was an investor at TPG Capital, a global
private investment firm with approximately $75 billion of assets under
management, where he helped lead teams that successfully completed
acquisitions having an aggregate value of over $10 billion. He served on
the boards of directors of RentPath and EnvisionRx, was an advisor to
the audit committee of Par Pharmaceutical and was a board observer to
IMS Health and Quintiles Transnational. Dr. Chacko currently serves as
the Chairperson of the Western Regional Selection Committee for the
Marshall Scholarship.

About Bonti

Bonti, based in Newport Beach, California, is a rapidly emerging
biotechnology company founded by world class neurotoxin and biologics
experts with proven prior success at Allergan and Halozyme. This team,
with deep neurotoxin, aesthetic and pain expertise, is uniquely
qualified to develop treatment paradigms driven by a novel neurotoxin
platform designed to become an innovative leader in both aesthetic and
therapeutic markets. By turning the science of neurotoxins into
beneficial patient and healthcare provider solutions, Bonti seeks to
improve lives by successfully addressing key unmet needs.

For more information, please visit

View Comments and Join the Discussion!